Anjan Thakurta - Concepedia

Author

Anjan Thakurta

Bristol-Myers Squibb (United States)ORCID

Also Known As

A G Thakurta, A Thakurta, A. Thakurta, Amelia Guha Thakurta, Anjan G Thakurta, Anjan G. Thakurta, Anjan Thakurta, Davies, Andrew, Thakurta, Anjan

312

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Harvard University Dana-Farber Cancer Institute Inserm University of Oxford

About

Anjan Thakurta is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	827
2	Health Sciences	7	7	510
3	Engineering	3	3	126
4	Natural Sciences	2	2	143
5	Biostatistics	1	1	49

Anjan Thakurta

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp> Anita K. Gandhi, Jian Kang, Courtney G. Havens, British Journal of Haematology	2013	611
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, Blood	2018	478
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, Leukemia	2018	440
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Michael Amatangelo, Lynn Quek, Alan H. Shih, Blood	2017	346
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 Chad C. Bjorklund, Ling Lu, Jian Kang, Blood Cancer Journal	2015	211
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL Patrick R. Hagner, Hon‐Wah Man, Celia Fontanillo, Blood	2015	197
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib Lynn Quek, Muriel D. David, Alison Kennedy, Nature Medicine Hematological MalignancyClonal HeterogeneityMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2018	193
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN Chad C. Bjorklund, Jian Kang, Michael Amatangelo, Leukemia Hematological MalignancyDysregulated CrbnImmunostimulatory ActivitiesImmunologyHematology	2019	188
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Myron S. Czuczman, Marek Trněný, Andrew Davies, Clinical Cancer Research	2017	164
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma Sarah Gooding, Naser Ansari‐Pour, Fadi Towfic, Blood	2020	151

Page 1